Home » Stocks » VXRT

Vaxart, Inc. (VXRT)

Stock Price: $8.14 USD -0.16 (-1.93%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $8.10 -0.04 (-0.49%) Jul 23, 7:58 PM
Market Cap 995.26M
Revenue (ttm) 1.65M
Net Income (ttm) -46.93M
Shares Out 122.27M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE 45.87
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $8.14
Previous Close $8.30
Change ($) -0.16
Change (%) -1.93%
Day's Open 8.25
Day's Range 7.88 - 8.31
Day's Volume 4,452,761
52-Week Range 3.50 - 24.90


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The first half has been a cycle of hope and disappointment for shareholders.

5 days ago - The Motley Fool

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Other stocks mentioned: BNTX, CODX, MRNA, NVAX, PFE
5 days ago - The Motley Fool

Analysts' high-water price targets imply some serious gains for these companies.

Other stocks mentioned: CCHWF, INO
1 week ago - The Motley Fool

VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day. The post Don't Count on a Covid-19 Boost for Vaxart appeared first on InvestorPl...

1 week ago - InvestorPlace

With the summer of recovery under way, these growth stocks could be your best bet.

Other stocks mentioned: DLTH, LOVE
1 week ago - The Motley Fool

Vaxart recently made a licensing deal, and two research firms issued upbeat assessments of the company, making me more upbeat on VXRT stock. The post New Developments Have Made Vaxart Stock So Much More...

1 week ago - InvestorPlace

Vaxart needs a Covid-19 vaccine approved and selling on the market before the established mega-cap names take all the sales. The post Watch Out for a Selloff in Vaxart Stock appeared first on InvestorPl...

2 weeks ago - InvestorPlace

Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.

2 weeks ago - Zacks Investment Research

Vaxart Inc (NASDAQ: VXRT) has granted Altesa Biosciences Inc an exclusive worldwide license to develop and commercialize Vaxart's patented formulation of the capsid-binding Vapendavir, a clinical-stage ...

2 weeks ago - Benzinga

Milestone payments up to $130 million and royalties for global Vapendavir sales

2 weeks ago - GlobeNewsWire

VXRT stock is known to be a fast mover. Any piece of good news could prove to be a multi-bagger for investors who take an early position.

2 weeks ago - InvestorPlace

VXRT stock just received a buy recommendation and a $13 price target from Jefferies, based on the promise of a oral vaccine instead of a needle. The post Will the Promise of Avoiding the Needle Pay Off ...

3 weeks ago - InvestorPlace

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: COTY, KGC, QCOM, SFT
4 weeks ago - 24/7 Wall Street

Today, VXRT stock is climbing higher on an otherwise red day for the markets, as many speculate retail investors could be behind this rise. The post VXRT Stock: Can Redditors Help Vaxart Power Higher?

1 month ago - InvestorPlace

Vaxart is still not worth today's price. VXRT stock is worth no more than $6, especially if it's going to need another capital raise.

1 month ago - InvestorPlace

Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

The declines appear to be caused simply by volatility that's common with small biotech stocks.

Other stocks mentioned: DVAX, NVAX
1 month ago - The Motley Fool

The science looks fishy for this small-cap biotech.

1 month ago - The Motley Fool

VXRT stock is on the move as the company received some very bullish coverage from an analyst initiating coverage today. The post VXRT Stock: Why Redditors Are Betting on a Big Squeeze With Vaxart Today ...

1 month ago - InvestorPlace

Investors are cheering an analyst's positive recommendation.

1 month ago - The Motley Fool

Are these former penny stocks on your watch list right now? The post 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other stocks mentioned: GTBP, NOVN, OCGN
1 month ago - PennyStocks

Vaxart Inc (NASDAQ:VXRT) shares are trading higher by 30% at $9.34 Friday morning after Piper Sandler initiated coverage on the stock with an Overweight rating and $18 price target. Vaxart is a clinical...

1 month ago - Benzinga

This isn't the first time its coronavirus vaccine pill has disappointed investors.

1 month ago - The Motley Fool

Reimagining Covid-19 vaccines isn't an easy task, but Vaxart is prepared to innovate - and VXRT stock could move higher at any given moment. The post Bet on a No-Needle Vaccine Strategy with Vaxart appe...

1 month ago - InvestorPlace

If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.

Other stocks mentioned: MGNI, PLUG, TCNNF, TDOC
1 month ago - The Motley Fool

The key is standing out from the crowd.

Other stocks mentioned: INO, MRNA, NVAX, PFE
1 month ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet ra...

1 month ago - GlobeNewsWire

As a company attempting to make oral vaccines, Vaxart has a compelling story. However VXRT stock looks to be many years away from paying off.

1 month ago - InvestorPlace

Prior to the vaccination rollout from Vaxart's competitors, VXRT stock appeared a compelling alternative. That's no longer the case.

1 month ago - InvestorPlace

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rat...

1 month ago - GlobeNewsWire

Vaxart's vaccine pill could prove to be effective against the original Covid-19 virus and its new variants, sending VXRT stock sky-high. The post Speculators Should Consider Buying Vaxart Stock appeared...

1 month ago - InvestorPlace

Penny stocks that left the nest in 2021 To Watch Right Now The post Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other stocks mentioned: ARDX, GTBP, PDSB
2 months ago - PennyStocks

VXRT Stock needs to nail the next few studies of its Covid 19 vaccine candidate and prove its thesis to widen its bull case significantly The post Vaxart Could Still Be a Viable Covid 19 Vaccine Play ap...

2 months ago - InvestorPlace

These two high-flying biotechs are vying for the same market.

Other stocks mentioned: OCGN
2 months ago - The Motley Fool

Vaxart stock is likely headed down 85% towards its cash per share. VXRT stock is not worth much more than $1.00 per share, so expect to see it drop 85%.

2 months ago - InvestorPlace

This is a risky play, with a catalyst that more likely than not won't pan out. But, if it releases more promising news within the coming months, it could go on yet another parabolic run.

2 months ago - InvestorPlace

Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Can this troubled coronavirus vaccine developer redeem itself and its investors?

2 months ago - The Motley Fool

VXRT stock is down from its highs, but there's no need to worry, as Vaxart has a unique Covid-19 vaccine and some encouraging clinical data. The post Vaxart's No-Shot Vaccine Is a Potential Game Changer...

2 months ago - InvestorPlace

As with most investment decisions, whether to hold depends on the situation. Here are some things to think about.

2 months ago - The Motley Fool

Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population

2 months ago - GlobeNewsWire

Here's how the biotechs compare on several key fronts.

Other stocks mentioned: OCGN
2 months ago - The Motley Fool

If it can reach the market of people that are hesitant to be vaccinated, yes.

2 months ago - The Motley Fool

Its coronavirus vaccine candidate may stand out, if upcoming trials are successful.

2 months ago - The Motley Fool

Investors are excited about the company's experimental COVID-19 vaccine.

2 months ago - The Motley Fool

The shares of biotechnology concern Vaxart Inc (NASDAQ:VXRT) are up a whopping 11.5% to trade at $8.94 at last check , after the company announced its oral coronavirus vaccine produced positive phase 1 ...

2 months ago - Schaeffers Research

Shareholders keep getting their hopes up for the company's tablet-based COVID-19 vaccine.

2 months ago - The Motley Fool

Vaxart Inc (NASDAQ: VXRT) has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1. Data obtained showed substantial CD8+ T-cell responses again...

2 months ago - Benzinga

Vaxart oral vaccine induced higher CD8 + T-Cell responses than those seen with  Moderna or Pfizer vaccines in comparative experiment conducted by the Company

2 months ago - GlobeNewsWire

Ocugen Inc. (NASDAQ: OCGN) and Vaxart Inc. (NASDAQ: VXRT) are moving Monday. Ocugen shares gapped higher after the company's studies showed that COVAXIN is potentially effective against three key varian...

Other stocks mentioned: OCGN
2 months ago - Benzinga

About VXRT

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, wh... [Read more...]

Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, Vaxart's revenue was $4.05 million, a decrease of -58.97% compared to the previous year's $9.86 million. Losses were -$32.22 million, 72.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Vaxart stock is "Strong Buy." The 12-month stock price forecast is 13.40, which is an increase of 64.62% from the latest price.

Price Target
(64.62% upside)
Analyst Consensus: Strong Buy